Obesity, Hypertension, Dyslipidemia
Conditions
Interventions
None listed
Sponsors
Department of Cardiovascular Medicine, Kyoto University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with dyslipidemia (TG >150 mg/dL at any time) and scheduled to receive pemafibrate. 2. obese patients 3. Patients with hypertension 4. Patients who have given written consent to participate in the clinical study
Exclusion criteria
Exclusion criteria: 1. Patients with contraindications to the target drug. 2. Patients with chronic atrial fibrillation or pacemaker implantation Patients with severe impairment of cardiovascular or pulmonary function such as shock, heart failure, myocardial infarction, pulmonary embolism, and other patients prone to hypoxemia. 4. Patients with excessive alcohol intake 5. Patients with severe infections, before and after surgery, or with severe trauma Patients with malnutrition, starvation, weakness, pituitary insufficiency, or adrenal insufficiency. 7. Other patients who are deemed inappropriate by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in LF/HF from baseline at 24 weeks post-treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in HF and LF from baseline at 24 weeks after initiation of treatment 2. Change from baseline at 24 weeks after the start of study treatment for the following 1) Change in heart rate variability index 2) Frequency of extrasystoles and arrhythmias 3) Body measurements: weight, BMI 4) Carotid artery IMT 5) Abdominal circumference, Catecholamine, General blood collection results | — |
Countries
Japan
Contacts
Public ContactKoh Ono
Kyoto University Graduate School of Medicine Department of Cardiovascular Medicine
Outcome results
None listed